Immunochemotherapy in Waldenström macroglobulinemia – still the backbone of treatment
- 12 May 2015
- journal article
- editorial
- Published by Taylor & Francis Ltd in Leukemia & Lymphoma
- Vol. 56 (9), 2489-2490
- https://doi.org/10.3109/10428194.2015.1058938
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Ibrutinib in Previously Treated Waldenström’s MacroglobulinemiaThe New England Journal of Medicine, 2015
- Treatment recommendations for patients with Waldenström macroglobulinemia (WM) and related disorders: IWWM-7 consensusBlood, 2014
- PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent LymphomaThe New England Journal of Medicine, 2014
- Waldenström's macroglobulinaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnnals of Oncology, 2013
- Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trialThe Lancet, 2013
- How to manage Waldenstrom’s macroglobulinemiaLeukemia, 2013
- Results of a Randomized Trial of Chlorambucil Versus Fludarabine for Patients With Untreated Waldenström Macroglobulinemia, Marginal Zone Lymphoma, or Lymphoplasmacytic LymphomaJournal of Clinical Oncology, 2013
- Bendamustine Therapy in Patients With Relapsed or Refractory Waldenström's MacroglobulinemiaClinical Lymphoma Myeloma and Leukemia, 2011
- Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapyLeukemia, 2010
- The incidence and survival of Waldenström's Macroglobulinaemia in South East EnglandLeukemia Research, 2008